Drug Discovery Featured Articles & Applications

  1. Your 3-Step Process For Innovation In Precision Medicine 8/3/2022

    Scientific advances are exciting, but not every discovery translates well into the clinic. Why is that? And how can companies successfully position themselves for market success with their drug discovery efforts? 

  2. Data: The Near Future Of Regulatory Info Management In Europe 7/29/2022

    Data, rather than static documents, is the future of regulatory information management. It also paves the way for information to be shared in different formats as use cases dictate, while still ensuring the consistency of the data. Even though regulators haven’t quite got their ducks in a row yet, they know full well that this is the scenario that everything is pointing toward. So, to prepare for anything less would be unwise.

  3. Can Molecular Modeling Overcome The Limitations Of Drug Discovery AI? 7/11/2022

    In small molecule drug development's search for computational approaches to assist drug discovery, there are limitations to using artificial intelligence (AI), the largest one being AI's data problem. How can molecular modeling overcome AI's limitations for more successful small molecule drug discovery?

  4. Nonprofit Drug Development: An Innovative Solution To Advancing Treatments For Rare Genetic Diseases 7/6/2022

    The challenges between rare diseases and traditional drug development mean the nonprofit approach might be the only chance left to move programs forward. 

  5. FDA Seeks Comment On ICH Q9(R1) Quality Risk Management 7/5/2022

    ICH has revised Q9 Quality Risk Management, providing principles and tools that can be applied throughout the product life cycle of drug substances, drug products, biological, and biotech products. The FDA, a founding member of the ICH, plays a major role in the development of ICH guidelines, which FDA then adopts and issues as guidance to industry. 

  6. Market Tumult And The Need For Creative Funding For Life Sciences 6/29/2022

    Life sciences companies have not been immune to the upheaval in the financial markets, casting a pall over equity financing in the sector. Your company will need to be creative in raising capital. This article also covers M&A, synthetic royalty agreements, convertible debt, and covenants. Will there be a reckoning?

  7. Mold Investigations Using Biofluorescent Particle Counting Systems 6/27/2022

    In the world of environmental monitoring in pharma manufacturing, it is common to rely on methods requiring media and subsequent incubation to detect microorganisms. For more extensive contamination events (e.g., mold occurrence), it is common to perform additional evaluations that can lead to extended downtime. 

  8. Why Russia's Invasion Of Ukraine Threatens Our Life Science Ecosystem 6/22/2022

    I posit that only pluralistic democracies committed to the rule of law can support the kind of investment and innovation our industry requires to thrive, while autocracies can’t make the same claim.

  9. How To Navigate The Patenting Challenges Of AI-Assisted Drug Discovery 6/17/2022

    With “low-hanging fruit” drugs already in the market, biopharma companies are finding it more difficult to discover the next blockbuster treatment. Artificial intelligence (AI) has become a new arrow in the drug discovery quiver. But how do you patent AI-assisted drug discovery? Attorneys from Haynes Boone provide recommendations.

  10. The Coming Wave Of Radio(bio)pharmaceuticals 6/13/2022

    Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling technologies improve on previous failures, CEO, CMO, and co-founder Dr. Philip Kantoff is projecting a new wave of activity in the space among biopharmas big and small.